In a landmark funding round, AI medical startup Abridge announced a $250 million raise that propels the company to a $2.75 billion valuation. The 2018-founded venture has established itself as a frontrunner in medical transcription technology, attracting major healthcare players as both investors and partners.
Founded by Dr. Shiv Rao, a practicing cardiologist with healthcare technology expertise, along with co-founders Florian Metze and Sandeep Konam from Carnegie Mellon, Abridge tackles one of healthcare’s most persistent pain points: clinical documentation.
“Our technology transforms the patient-doctor conversation into structured clinical notes in real time,” says Abridge. “This allows physicians to focus on patients instead of paperwork, addressing a major source of burnout in healthcare.”
The company’s specialized generative AI sets it apart from generic transcription tools. Trained on medical dialogues, the system captures nuanced terminology and produces accurate notes that integrate with electronic health record systems like Epic.
This integration capability has helped Abridge secure partnerships with healthcare giants including Kaiser Permanente and Mayo Clinic. Thousands of clinicians now use the platform daily across multiple health systems.
Abridge has built momentum through strategic executive hires, including a new CTO and COO, preparing for rapid growth across the U.S. healthcare market.
The future roadmap includes expanding EHR integrations beyond Epic and enhancing AI capabilities for multilingual support. The company aims to become the global standard for clinical documentation, with an ambitious goal of reducing healthcare administrative costs by 50%.
This funding validates Abridge’s approach to solving healthcare inefficiencies through purpose-built AI, positioning the startup at the intersection of artificial intelligence and healthcare transformation.
The company continues to scale its team while focusing on its core mission: freeing physicians from documentation burdens so they can concentrate on patient care. With its latest funding, Abridge appears positioned to accelerate this vision across the healthcare landscape.
